<GlossaryTerm id="CDR0000796968"><TermName>caplacizumab</TermName><TermPronunciation>(KAP-luh-SIH-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A drug used with plasma exchange and immunosuppressive therapy to treat acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare blood disorder in which blood clots form in small blood vessels throughout the body. Caplacizumab binds to a protein called VWF, which may help keep blood clots from forming. It is a type of nanobody (a tiny antibody). Also called Cablivi.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000797995" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;caplacizumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000797994" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;caplacizumab&quot;" language="es" id="_4"/><SpanishTermName>caplacizumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa con la plasmaféresis y la terapia inmunodepresora para tratar la púrpura
trombocitopénica trombótica (PTT) adquirida. La PTT adquirida es un trastorno sanguíneo poco frecuente por el que se forman coágulos sanguíneos de sangre en los vasos sanguíneos pequeños de todo el cuerpo. El caplacizumab se une a una proteína, el factor de Von Willebrand (VWF), que tal vez evite que se formen  coágulos sanguíneos. Es un tipo de nanoanticuerpo (anticuerpo diminuto). También se llama Cablivi.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2019-02-13</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000796985" url="/about-cancer/treatment/drugs/caplacizumab-yhdp">Caplacizumab-yhdp</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
